Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Major Depressive Disorder blood gene expression


ABSTRACT: Background: Major Depressive Disorder (MDD) is a moderately heritable disorder with a high lifetime prevalence. At present, laboratory blood tests to support MDD diagnosis are not available. Methods: We used a classifier approach on blood gene expression profiles of a unique set of non-medicated subjects (MDD patients and controls) to select genes of which expression is predictive for disease status. To reveal blood gene expression changes related to MDD disease, we applied a powerful ex vivo stimulus to the blood, i.e. incubation with lipopolysaccharide (LPS; 10 ng/ml blood). Results: Based on LPS-stimulated blood gene expression using whole-genome microarrays in 42 subjects (primary cohort; 21 MDD patients (mean age 42.3 years), 21 healthy controls (mean age 41.9 years)), we identified a set of genes (CAPRIN1, CLEC4A, KRT23, MLC1, PLSCR1, PROK2, ZBTB16) that serves as a molecular signature of MDD. These findings were validated for the primary cohort using an independent quantitative PCR method (P = 0.007). The difference between depressive patients and controls was confirmed (P = 0.019) in a replication cohort of 13 patients with MDD (mean age 42.8 years) and 14 controls (mean age 45.6 years). The MDD-signature score comprised of expression levels of 7 genes could discriminate depressive patients from controls with sensitivity of 76.9% and specificity of 71.8%. Conclusions: We show for the first time that molecular analysis of stimulated blood cells can be used as an endophenotype for MDD diagnosis, which is a milestone in establishing biomarkers for neuropsychiatric disorders with moderate heritability in general. Our results may provide a new entry point for following and predicting treatment outcome, as well as prediction of severity and recurrence of MDD. In total, 33 MDD patients and 34 healthy controls were analyzed using basal gene expression in whole blood, and gene expression from whole blood that was stimulated with LPS for 5-6 h, using microarrays. Patients were arbitrarily selected from all patients to serve as primary cohort (nMDD = 21 (MDD01-MDD21); nControls = 21 (Con01-Con21)), or replication cohort (nMDD = 12 (MDD22-MDD35); nControls = 13 (Con22-Con37)) using microarrays. This submission does not include Samples CON21_LPS or CON30_LPS.

ORGANISM(S): Homo sapiens

SUBMITTER: sabine Spijker 

PROVIDER: E-GEOD-19738 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Stimulated gene expression profiles as a blood marker of major depressive disorder.

Spijker Sabine S   Van Zanten Jeroen S JS   De Jong Simone S   Penninx Brenda W J H BW   van Dyck Richard R   Zitman Frans G FG   Smit Jan H JH   Ylstra Bauke B   Smit August B AB   Hoogendijk Witte J G WJ  

Biological psychiatry 20100514 2


<h4>Background</h4>Major depressive disorder (MDD) is a moderately heritable disorder with a high lifetime prevalence. At present, laboratory blood tests to support MDD diagnosis are not available.<h4>Methods</h4>We used a classifier approach on blood gene expression profiles of a unique set of unmedicated subjects (MDD patients and control subjects) to select genes with expression predictive for disease status. To reveal blood gene expression changes related to major depressive disorder-disease  ...[more]

Similar Datasets

2011-10-05 | GSE19738 | GEO
2016-01-14 | E-GEOD-76826 | biostudies-arrayexpress
2016-01-14 | GSE76826 | GEO
2022-05-20 | PXD028947 | Pride
2022-11-03 | GSE198904 | GEO
2022-02-16 | PXD028841 | Pride
2014-01-25 | E-GEOD-54370 | biostudies-arrayexpress
2012-03-21 | E-GEOD-32280 | biostudies-arrayexpress
2023-04-13 | PXD023009 | Pride
2013-07-31 | E-GEOD-46914 | biostudies-arrayexpress